Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008213 | 0.91 | RAF1 (0.38) | RAF1BRAFPIK3CAMTORABL1 | |
| SCHEMBL20008422 | 0.85 | PIK3CA (0.38) | RAF1BRAFPIK3CAMTORPDCD1 | |
| SCHEMBL20009647 | 0.77 | BRAF (0.47) | RAF1BRAF | |
| SCHEMBL20008211 | 0.77 | BRAF (0.36) | RAF1BRAFPIK3CAPDCD1CD274 | |
| SCHEMBL20008778 | 0.74 | RAF1 (0.37) | RAF1BRAFROCK2ROCK1 | |
| SCHEMBL20009415 | 0.73 | RAF1 (0.37) | RAF1BRAF | |
| SCHEMBL20009117 | 0.70 | RAF1 (0.40) | RAF1BRAFMAPT | |
| SCHEMBL20009443 | 0.69 | RAF1 (0.37) | RAF1BRAFROCK2ROCK1 | |
| SCHEMBL20008259 | 0.69 | RAF1 (0.38) | RAF1BRAF | |
| SCHEMBL20009709 | 0.69 | BRAF (0.39) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |